Login Register Cart 0
Generic placeholder image

Current Psychopharmacology

Editor-in-Chief

ISSN (Print): 2211-5560
ISSN (Online): 2211-5579

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Comprehensive Review on the Neuropharmacological Effects of Antidepressants in Various Prospects

Author(s): Sandesh Varshney, Md. Aftab Alam*, Awaneet Kaur* and Shaweta Sharma*

Volume 12, 2024

Published on: 13 July, 2023

Article ID: e070723218522 Pages: 21

DOI: 10.2174/2211556011666230707122341

Price: $65

Abstract

Depression is one of the most challenging diseases for society to treat. It is a highly prevalent and disabling illness in the general population. Affective disorders are characterised by depressed mood, diminished interest and pleasure, feelings of guilt or poor self-worth, sleep or food difficulties, decreased energy, and impaired attention. This manuscript will look at depression from a behavioural analytic perspective. The pathogenesis of major depressive disorder is poorly understood. Several lines of experimental and clinical evidence, however, show that the therapeutic effect of most antidepressant drugs is related to an increase in 5-HT-mediated neurotransmission. Alternative techniques, however, are employed to obtain this net effect. A better understanding of the neurological mechanism underpinning antidepressant drugs' delayed onset of action has resulted in the development of ways to accelerate antidepressant responses, which are discussed further below. Many antidepressant medications on the market today are beneficial, but they come with many downsides, including unpleasant side effects, potential interactions, and a low response rate. Natural drugs, on the other hand, are extremely effective, have a low risk, and a limited amount of side effects, which are covered briefly in this paper. Alternative modalities of administration have received a lot of attention in recent decades as a complement to approved prescription pharmaceuticals, especially for people who cannot tolerate oral or parenteral methods. The most promising non-invasive systemic delivery techniques are transdermal and transbronchial administration, and these are the focus of this research.

Keywords: Depression, disabling illness, behavioural analytic perspective, antidepressant drugs, 5-HT-mediated neurotransmission, transdermal.

[1]
Srivastava S, Bohra N, Bhatia MS. Depression in women in Indian context. Indian J Psychiatry 2015; 57(6)(S2): 239.
[http://dx.doi.org/10.4103/0019-5545.161485] [PMID: 26330641]
[2]
Anisman H, Zacharko RM. Depression: The predisposing influence of stress. Behavioral and Brain Sciences. Behav Brain Sci 1982; 5(1): 89-99.
[http://dx.doi.org/10.1017/S0140525X00010633]
[3]
Chuang CY, Shi YC, You HP, Lo YH, Pan TM. Antidepressant effect of GABA-rich monascus-fermented product on forced swimming rat model. J Agric Food Chem 2011; 59(7): 3027-34.
[http://dx.doi.org/10.1021/jf104239m] [PMID: 21375324]
[4]
Xu Q, Pan Y, Yi LT, et al. Antidepressant-like effects of psoralen isolated from the seeds of Psoralea corylifolia in the mouse forced swimming test. Biol Pharm Bull 2008; 31(6): 1109-14.
[http://dx.doi.org/10.1248/bpb.31.1109] [PMID: 18520040]
[5]
Mukherjee PK, Kumar V, Mal M, Houghton PJ. Acorus calamus: Scientific validation of ayurvedic tradition from natural resources. Pharm Biol 2007; 45(8): 651-66.
[http://dx.doi.org/10.1080/13880200701538724]
[6]
Lewis G. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. 1996; p. 886.
[http://dx.doi.org/10.1017/S0033291700035765]
[7]
Keller MB, Hirschfeld RMA, Hanks D. Double depression: A distinctive subtype of unipolar depression. J Affect Disord 1997; 45(1-2): 65-73.
[http://dx.doi.org/10.1016/S0165-0327(97)00060-8] [PMID: 9268776]
[8]
Ashok Kumar BS, Lakshman K, Velmurugan C, Sridhar SM, Gopisetty S. Antidepressant activity of methanolic extract of amaranthus spinosus. Basic Clin Neurosci 2014; 5(1): 11-7.
[PMID: 25436078]
[9]
Badhe SR, Badhe RV, Ghaisas MM, Chopade VV, Deshpande AD. Evaluations of antidepressant activity of Anacyclus pyrethrum root extract. Int J Green Pharm 2010; 4(2): 79.
[http://dx.doi.org/10.4103/0973-8258.63880]
[10]
Shalam MD, Shantakumar SM, Narasu ML. Pharmacological and biochemical evidence for the antidepressant effect of the herbal preparation Trans-01. Indian J Pharmacol 2007; 39(5): 231.
[http://dx.doi.org/10.4103/0253-7613.37273]
[11]
Nadkarni AK. Indian Materica Medica. (3rd ed.). Mumbai: Popular Publication 2000; Vol. 1: pp. 97-8.
[12]
Wattanathorn J, Pangpookiew P, Sripanidkulchai K, Muchimapura S, Sripanidkuchai B. Evaluation of the anxiolytic and antidepressant effects of alcoholic extract of Kaempferia parviflora in aged rats. Am J Agric Biol Sci 2007; 2(2): 1-6.
[13]
Buchbauer G, Jirovetz L, Jäger W, Dietrich H, Plank C. Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation. Z Naturforsch C J Biosci 1991; 46(11-12): 1067-72.
[http://dx.doi.org/10.1515/znc-1991-11-1223] [PMID: 1817516]
[14]
Lekamge S, Nakachi M, Sato S, Ito K, Nomura S. Alleviation of the acute stress response following mild orange essential oil administration. IEEJ Trans Electr Electron Eng 2017; 12: S158-63.
[http://dx.doi.org/10.1002/tee.22428]
[15]
Buchbauer G, Jager W, Jirovetz L, Ilmberger J, Dietrich H. Therapeutic properties of essential oils and fragrances Bioactive volatile compounds from plants. Washington, DC: American Chemical Society 1993; pp. 159-65.
[http://dx.doi.org/10.1021/bk-1993-0525.ch012]
[16]
Jawaid TA, Imam SA, Kamal ME. Antidepressant activity of methanolic extract of Verbena Officinalis Linn. plant in mice. Asian J Pharm Clin Res 2015; 8(4): 308-10.
[17]
Sharma VK, Chauhan NS, Lodhi S, Singhai AK. Anti-depressant activity of Zizyphus xylopyrus. Int J Phytomed 2009; 1(1): 12-7.
[http://dx.doi.org/10.5138/ijpm.2009.0975.0185.05788]
[18]
Pisani G, Facioni L, Fiorani F, Pisani G. Psychosexual problems in menopause. Minerva Ginecol 1998; 50(3): 77-81.
[PMID: 9595919]
[19]
Kessler R, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. J Affect Disord 1993; 29(2-3): 85-96.
[http://dx.doi.org/10.1016/0165-0327(93)90026-G] [PMID: 8300981]
[20]
Birkhäuser M. Depression, menopause and estrogens: is there a correlation? Maturitas 2002; 41 (Suppl. 1): 3-8.
[http://dx.doi.org/10.1016/S0378-5122(02)00009-9] [PMID: 11955789]
[21]
Taylor M. Psychological consequences of surgical menopause. J Reprod Med 2001; 46(3) (Suppl.): 317-24.
[PMID: 11304879]
[22]
Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59(12): 1151-9.
[http://dx.doi.org/10.1016/j.biopsych.2005.09.018] [PMID: 16566899]
[23]
1995.
[http://dx.doi.org/10.1176/ajp.152.8.1228]
[24]
World Health Organization. The ICD-10 Classification of mental and behaviour disorder: clinical descriptions and diagnostic guidelines. Geneva: WHO 1992.
[25]
Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001; 2(5): 343-51.
[http://dx.doi.org/10.1038/35072566] [PMID: 11331918]
[26]
Diagnostic and statistical manual for mental disorders. 4th ed. DSM-IV. Washington, D.C.: American Psychiatric Press 2000. Available From: https://www.psychiatry.org/psychiatrists/practice/dsm
[27]
Ashwani A, Preeti V. Review article a review on pathophysiology. Classification And Longterm Course Of Depression 2012; 3(3): 90-6.
[28]
Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28(2): 335-41.
[http://dx.doi.org/10.1016/S0896-6273(00)00112-4] [PMID: 11144343]
[29]
Atzori M, Cuevas-Olguin R, Esquivel-Rendon E, et al. Locus ceruleus norepinephrine release: a central regulator of CNS spatio-temporal activation? Front Synaptic Neurosci 2016; 8: 25.
[http://dx.doi.org/10.3389/fnsyn.2016.00025] [PMID: 27616990]
[30]
Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci 2016; 17(8): 524-32.
[http://dx.doi.org/10.1038/nrn.2016.57] [PMID: 27256556]
[31]
Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998; 59(4): 5-14.
[PMID: 9554316]
[32]
Maes M. The serotonin hypothesis of depression. In: Psychopharmacology: the fourth generation of progress. 1995; pp. 933-44.
[33]
Perry EK, Marshall EF, Blessed G, Tomlinson BE, Perry RH. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 1983; 142(2): 188-92.
[http://dx.doi.org/10.1192/bjp.142.2.188] [PMID: 6839075]
[34]
Craddock N, Khodel V, Van Eerdewegh P, Reich T. Mathematical limits of multilocus models: The genetic transmission of bipolar disorder. Am J Hum Genet 1995; 57(3): 690-702.
[PMID: 7668299]
[35]
López León S, Croes EA, Sayed-Tabatabaei FA, Claes S, Broeckhoven CV, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: A meta-analysis. Biol Psychiatry 2005; 57(9): 999-1003.
[http://dx.doi.org/10.1016/j.biopsych.2005.01.030] [PMID: 15860340]
[36]
López-León S, Janssens ACJW, González-Zuloeta Ladd AM, et al. Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry 2008; 13(8): 772-85.
[http://dx.doi.org/10.1038/sj.mp.4002088] [PMID: 17938638]
[37]
Thase ME, Howland RH. Biological processes in depression: An updated review and integration. In: Beckham EE, Ed. Handbook of depression. Guilford: Leber WR New York 1995; pp. 213-79.
[38]
Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. Psychol Bull 2004; 130(4): 601-30.
[http://dx.doi.org/10.1037/0033-2909.130.4.601] [PMID: 15250815]
[39]
Dinarello CA. Role of pro- and anti-inflammatory cytokines during inflammation: Experimental and clinical findings. J Biol Regul Homeost Agents 1997; 11(3): 91-103.
[PMID: 9498158]
[40]
Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009; 42(5): 182-8.
[http://dx.doi.org/10.1055/s-0029-1202263] [PMID: 19724980]
[41]
Henn FA, Vollmayr B. Neurogenesis and depression: Etiology or epiphenomenon? Biol Psychiatry 2004; 56(3): 146-50.
[http://dx.doi.org/10.1016/j.biopsych.2004.04.011] [PMID: 15271582]
[42]
Bjørnebekk A, Mathé AA, Brené S. The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. Hippocampus 2009; 20(7): 820-8.
[http://dx.doi.org/10.1002/hipo.20683] [PMID: 19623606]
[43]
Haynes SN, O’Brien WH. Functional analysis in behavior therapy. Clin Psychol Rev 1990; 10(6): 649-68.
[http://dx.doi.org/10.1016/0272-7358(90)90074-K]
[44]
Hawkins RP. Selection of target behaviours Conceptual foundations of behavioural assessment. New York: Guilford Press 1986; pp. 329-85.
[http://dx.doi.org/10.1016/S0005-7894(96)80047-5]
[45]
Hanley GP, Iwata BA, McCord BE. Functional analysis of problem behavior: a review. J Appl Behav Anal 2003; 36(2): 147-85.
[http://dx.doi.org/10.1901/jaba.2003.36-147] [PMID: 12858983]
[46]
Renner KE. Delay of reinforcement: A historical review. Psychol Bull 1964; 61(5): 341-61.
[http://dx.doi.org/10.1037/h0048335] [PMID: 14146339]
[47]
Kohlenberg RJ, Tsai M, Dougher MJ. The dimensions of clinical behavior analysis. Behav Anal 1993; 16(2): 271-82.
[http://dx.doi.org/10.1007/BF03392636] [PMID: 22478158]
[48]
Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol 2013; 69(4): 755-60.
[http://dx.doi.org/10.1007/s00228-012-1408-1] [PMID: 22996077]
[49]
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline. Int Clin Psychopharmacol 2014; 29(4): 185-96.
[http://dx.doi.org/10.1097/YIC.0000000000000023] [PMID: 24424469]
[50]
Amidfar M, Kim YK. Recent developments on future antidepressant-related serotonin receptors. Curr Pharm Des 2018; 24(22): 2541-8.
[http://dx.doi.org/10.2174/1381612824666180803111240] [PMID: 30073919]
[51]
Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19(3): 149-55.
[http://dx.doi.org/10.1097/00004850-200405000-00005] [PMID: 15107657]
[52]
Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry 2019; 13(5): 1032-49.
[http://dx.doi.org/10.1111/eip.12775] [PMID: 30690898]
[53]
Saad MA, El-Sahar AE, Sayed RH, Elbaz EM, Helmy HS, Senousy MA. Venlafaxine mitigates depressive-like behavior in ovariectomized rats by activating the EPO/EPOR/JAK2 signaling pathway and increasing the serum estradiol level. Neurotherapeutics 2019; 16(2): 404-15.
[http://dx.doi.org/10.1007/s13311-018-00680-6] [PMID: 30361931]
[54]
Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14(6): 457-70.
[http://dx.doi.org/10.1016/j.euroneuro.2004.01.002] [PMID: 15589385]
[55]
Fred SM, Laukkanen L, Brunello CA, et al. Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2. J Biol Chem 2019; 294(48): 18150-61.
[http://dx.doi.org/10.1074/jbc.RA119.008837] [PMID: 31631060]
[56]
Ziegler C, Domschke K. Epigenetic signature of MAOA and MAOB genes in mental disorders. J Neural Transm 2018; 125(11): 1581-8.
[http://dx.doi.org/10.1007/s00702-018-1929-6] [PMID: 30242487]
[57]
Fagiolini A, Comandini A, Dell’Osso MC, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012; 26(12): 1033-49.
[http://dx.doi.org/10.1007/s40263-012-0010-5] [PMID: 23192413]
[58]
Paccosi S, Cresci B, Pala L, Rotella CM, Parenti A. Obesity therapy: How and why? Curr Med Chem 2020; 27(2): 174-86.
[http://dx.doi.org/10.2174/0929867326666190124121725] [PMID: 30678612]
[59]
Schwasinger-Schmidt TE, Macaluso M. Other antidepressants InAntidepressants. Cham: Springer 2018; pp. 325-55.
[http://dx.doi.org/10.1007/164_2018_167]
[60]
Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151(6): 737-48.
[http://dx.doi.org/10.1038/sj.bjp.0707253] [PMID: 17471183]
[61]
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Natl Inst Diabetes Digestive Kidney Dis 2018.
[62]
Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 1(1): CD011209.
[http://dx.doi.org/10.1002/14651858.cd011209.pub] [PMID: 25569864]
[63]
Riediger C, Schuster T, Barlinn K, Maier S, Weitz J, Siepmann T. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis. Front Neurol 2017; 8: 307.
[http://dx.doi.org/10.3389/fneur.2017.00307] [PMID: 28769859]
[64]
Gutman DA, Gutman AR, Owens MJ, Nemeroff CB. Stress neurobiology and corticotropin-releasing factor. Psychiatr Times 2006; 23(10): 91.
[65]
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160(1): 1-12.
[http://dx.doi.org/10.1677/joe.0.1600001] [PMID: 9854171]
[66]
Bittencourt JC, Benoit R, Sawchenko PE. Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: Partial overlap with ascending catecholaminergic projections. J Chem Neuroanat 1991; 4(1): 63-78.
[http://dx.doi.org/10.1016/0891-0618(91)90032-8] [PMID: 1707281]
[67]
Culman J, Unger T. Central tachykinins: Mediators of defence reaction and stress reactions. Can J Physiol Pharmacol 1995; 73(7): 885-91.
[http://dx.doi.org/10.1139/y95-122] [PMID: 8846426]
[68]
Argyropoulos SV, Nutt DJ. Substance P antagonists: Novel agents in the treatment of depression. Expert Opin Investig Drugs 2000; 9(8): 1871-5.
[http://dx.doi.org/10.1517/13543784.9.8.1871] [PMID: 11060783]
[69]
Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989; 46(1): 45-50.
[http://dx.doi.org/10.1001/archpsyc.1989.01810010047007] [PMID: 2491941]
[70]
Wecker L, James S, Copeland N, Pacheco MA. Transdermal selegiline: Targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003; 54(10): 1099-104.
[http://dx.doi.org/10.1016/S0006-3223(02)01892-9] [PMID: 14625153]
[71]
Dailly E, Chenu F, Renard CE, Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol 2004; 18(6): 601-7.
[http://dx.doi.org/10.1111/j.1472-8206.2004.00287.x] [PMID: 15548230]
[72]
Beer B, Stark J, Krieter P, et al. DOV 216,303, a “triple” reuptake inhibitor: Safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004; 44(12): 1360-7.
[http://dx.doi.org/10.1177/0091270004269560] [PMID: 15545306]
[73]
Mayberg HS. Positron emission tomography imaging in depression: A neural systems perspective. Neuroimaging Clin N Am 2003; 13(4): 805-15.
[http://dx.doi.org/10.1016/S1052-5149(03)00104-7] [PMID: 15024963]
[74]
Cosgrove GR, Rauch SL. Stereotactic cingulotomy. Neurosurg Clin N Am 2003; 14(2): 225-35.
[http://dx.doi.org/10.1016/S1042-3680(02)00115-8] [PMID: 12856490]
[75]
Bakewell CJ, Russo J, Tanner C, Avery DH, Neumaier JF. Comparison of clinical efficacy and side effects for bitemporal and bifrontal electrode placement in electroconvulsive therapy. J ECT 2004; 20(3): 145-53.
[http://dx.doi.org/10.1097/00124509-200409000-00005] [PMID: 15342998]
[76]
Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: Randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology 2003; 28(10): 1852-65.
[http://dx.doi.org/10.1038/sj.npp.1300229] [PMID: 12865903]
[77]
Deuschl G, Wenzelburger R, Kopper F, Volkmann J. Deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: A therapy approaching evidence-based standards. J Neurol 2003; 250(S1): i43-6.
[http://dx.doi.org/10.1007/s00415-003-1109-8] [PMID: 12761636]
[78]
Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov Disord 2003; 18(11): 1332-7.
[http://dx.doi.org/10.1002/mds.10518] [PMID: 14639676]
[79]
Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 2009; 117 (Suppl. 1): S15-25.
[http://dx.doi.org/10.1016/j.jad.2009.06.042] [PMID: 19682749]
[80]
Vittengl JR, Clark LA, Jarrett RB. Continuation-phase cognitive therapy’s effects on remission and recovery from depression. J Consult Clin Psychol 2009; 77(2): 367-71.
[http://dx.doi.org/10.1037/a0015238] [PMID: 19309197]
[81]
Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62(4): 417-22.
[http://dx.doi.org/10.1001/archpsyc.62.4.417] [PMID: 15809409]
[82]
Cuijpers P, van Straten A, Warmerdam L, Andersson G. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis. Depress Anxiety 2009; 26(3): 279-88.
[http://dx.doi.org/10.1002/da.20519] [PMID: 19031487]
[83]
Kessler D, Lewis G, Kaur S, et al. Therapist-delivered internet psychotherapy for depression in primary care: A randomised controlled trial. Lancet 2009; 374(9690): 628-34.
[http://dx.doi.org/10.1016/S0140-6736(09)61257-5] [PMID: 19700005]
[84]
Simon GE, Ludman EJ, Rutter CM. Incremental benefit and cost of telephone care management and telephone psychotherapy for depression in primary care. Arch Gen Psychiatry 2009; 66(10): 1081-9.
[http://dx.doi.org/10.1001/archgenpsychiatry.2009.123] [PMID: 19805698]
[85]
Weissman M, Markowitz J. Clinician’s quick guide to interpersonal psychotherapy. Oxford University Press 2007.
[http://dx.doi.org/10.1093/med:psych/9780195309416.001.0001]
[86]
Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive–behavioural therapy for depression. Br J Psychiatry 2007; 190(6): 496-502.
[http://dx.doi.org/10.1192/bjp.bp.106.024729] [PMID: 17541109]
[87]
Schramm E, van Calker D, Dykierek P, et al. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: Acute and long-term results. Am J Psychiatry 2007; 164(5): 768-77.
[http://dx.doi.org/10.1176/ajp.2007.164.5.768] [PMID: 17475736]
[88]
Frank E, Kupfer D, Bysse D. Randomised trial of weekly, twice-monthly, monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007; 164(5): 761-7.
[http://dx.doi.org/10.1176/ajp.2007.164.5.761] [PMID: 17475735]
[89]
Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: A meta-analytic review. Focus Am Psychiatr Publ 2008; 6(1): 155-62.
[http://dx.doi.org/10.1176/foc.6.1.foc155]
[90]
Kim DR, Pesiridou A, O’Reardon JP. Transcranial magnetic stimulation in the treatment of psychiatric disorders. Curr Psychiatry Rep 2009; 11(6): 447-52.
[http://dx.doi.org/10.1007/s11920-009-0068-z] [PMID: 19909666]
[91]
Slotema CW, Blom JD, Hoek HW, Sommer IEC. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010; 71(7): 873-84.
[http://dx.doi.org/10.4088/JCP.08m04872gre] [PMID: 20361902]
[92]
Giacobbe P, Kennedy SH. Deep brain stimulation for treatment-resistant depression: A psychiatric perspective. Curr Psychiatry Rep 2006; 8(6): 437-44.
[http://dx.doi.org/10.1007/s11920-006-0048-5] [PMID: 17094923]
[93]
Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54(7): 597-606.
[http://dx.doi.org/10.1001/archpsyc.1997.01830190015002] [PMID: 9236543]
[94]
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59(12): 1116-27.
[http://dx.doi.org/10.1016/j.biopsych.2006.02.013] [PMID: 16631126]
[95]
Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112(2): 257-69.
[http://dx.doi.org/10.1016/S0092-8674(03)00035-7] [PMID: 12553913]
[96]
Chiaruttini C, Vicario A, Li Z, et al. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc Natl Acad Sci USA 2009; 106(38): 16481-6.
[http://dx.doi.org/10.1073/pnas.0902833106] [PMID: 19805324]
[97]
Machado DG, Bettio LEB, Cunha MP, et al. Antidepressant-like effect of rutin isolated from the ethanolic extract from Schinus molle L. in mice: Evidence for the involvement of the serotonergic and noradrenergic systems. Eur J Pharmacol 2008; 587(1-3): 163-8.
[http://dx.doi.org/10.1016/j.ejphar.2008.03.021] [PMID: 18457827]
[98]
Freitas AE, Budni J, Lobato KR, et al. Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: Evidence for the involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(2): 335-43.
[http://dx.doi.org/10.1016/j.pnpbp.2009.12.010] [PMID: 20026371]
[99]
Sánchez-Mateo CC, Bonkanka CX, Prado B, Rabanal RM. Antidepressant activity of some Hypericum reflexum L. fil. extracts in the forced swimming test in mice. J Ethnopharmacol 2007; 112(1): 115-21.
[http://dx.doi.org/10.1016/j.jep.2007.02.019] [PMID: 17383128]
[100]
Singh GK, Garabadu D, Muruganandam AV, Joshi VK, Krishnamurthy S. Antidepressant activity of Asparagus racemosus in rodent models. Pharmacol Biochem Behav 2009; 91(3): 283-90.
[http://dx.doi.org/10.1016/j.pbb.2008.07.010] [PMID: 18692086]
[101]
Lee S, Kim DH, Lee CH, et al. Antidepressant-like activity of the aqueous extract of Allium macrostemon in mice. J Ethnopharmacol 2010; 131(2): 386-95.
[http://dx.doi.org/10.1016/j.jep.2010.07.015] [PMID: 20637276]
[102]
Yi LT, Xu Q, Li YC, Yang L, Kong LD. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(4): 616-24.
[http://dx.doi.org/10.1016/j.pnpbp.2009.03.001] [PMID: 19285110]
[103]
Galdino PM, Nascimento MVM, Sampaio BL, Ferreira RN, Paula JR, Costa EA. Antidepressant-like effect of Lafoensia pacari A. St.-Hil. ethanolic extract and fractions in mice. J Ethnopharmacol 2009; 124(3): 581-5.
[http://dx.doi.org/10.1016/j.jep.2009.05.001] [PMID: 19439172]
[104]
Hattesohl M, Feistel B, Sievers H, Lehnfeld R, Hegger M, Winterhoff H. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 2008; 15(1-2): 2-15.
[http://dx.doi.org/10.1016/j.phymed.2007.11.027] [PMID: 18160026]
[105]
Capra JC, Cunha MP, Machado DG, et al. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems. Eur J Pharmacol 2010; 643(2-3): 232-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.06.043] [PMID: 20599906]
[106]
Rodrigues ALS, da Silva GL, Mateussi AS, et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 2002; 70(12): 1347-58.
[http://dx.doi.org/10.1016/S0024-3205(01)01498-9] [PMID: 11885577]
[107]
Guadarrama-Cruz G, Alarcon-Aguilar FJ, Lezama-Velasco R, Vazquez-Palacios G, Bonilla-Jaime H. Antidepressant-like effects of Tagetes lucida Cav. in the forced swimming test. J Ethnopharmacol 2008; 120(2): 277-81.
[http://dx.doi.org/10.1016/j.jep.2008.08.013] [PMID: 18782612]
[108]
Machado DG, Bettio LEB, Cunha MP, et al. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: Involvement of the monoaminergic system. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(4): 642-50.
[http://dx.doi.org/10.1016/j.pnpbp.2009.03.004] [PMID: 19286446]
[109]
Wang Y, Han T, Zhu Y, et al. Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J Nat Med 2010; 64(1): 24-30.
[http://dx.doi.org/10.1007/s11418-009-0360-6] [PMID: 19787421]
[110]
Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 2002; 83(1-2): 161-5.
[http://dx.doi.org/10.1016/S0378-8741(02)00211-8] [PMID: 12413724]
[111]
Sánchez-Mateo CC, Bonkanka CX, Prado B, Rabanal RM. Antidepressant properties of some Hypericum canariense L. and Hypericum glandulosum Ait. extracts in the forced swimming test in mice. J Ethnopharmacol 2005; 97(3): 541-7.
[http://dx.doi.org/10.1016/j.jep.2004.12.019] [PMID: 15740893]
[112]
Bhattamisra SK, Khanna VK, Agrawal AK, Singh PN, Singh SK. Antidepressant activity of standardised extract of Marsilea minuta Linn. J Ethnopharmacol 2008; 117(1): 51-7.
[http://dx.doi.org/10.1016/j.jep.2008.01.012] [PMID: 18299179]
[113]
Kwon S, Lee B, Kim M, Lee H, Park HJ, Hahm DH. Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(2): 265-70.
[http://dx.doi.org/10.1016/j.pnpbp.2009.11.015] [PMID: 19932727]
[114]
Maity TK, Mandal SC, Saha BP, Pal M. Effect of Ocimum sanctum roots extract on swimming performance in mice. Phytother Res 2000; 14(2): 120-1.
[http://dx.doi.org/10.1002/(SICI)1099-1573(200003)14:2<120::AID-PTR557>3.0.CO;2-0] [PMID: 10685110]
[115]
Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 2008; 589(1-3): 163-72.
[http://dx.doi.org/10.1016/j.ejphar.2008.05.043] [PMID: 18585703]
[116]
Sairam K, Dorababu M, Goel RK, Bhattacharya SK. Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats. Phytomedicine 2002; 9(3): 207-11.
[http://dx.doi.org/10.1078/0944-7113-00116] [PMID: 12046860]
[117]
Yao CY, Wang J, Dong D, Qian FG, Xie J, Pan SL. Laetispicine, an amide alkaloid from Piper laetispicum, presents antidepressant and antinociceptive effects in mice. Phytomedicine 2009; 16(9): 823-9.
[http://dx.doi.org/10.1016/j.phymed.2009.02.008] [PMID: 19447013]
[118]
Sakakibara H, Ishida K, Grundmann O, et al. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biol Pharm Bull 2006; 29(8): 1767-70.
[http://dx.doi.org/10.1248/bpb.29.1767] [PMID: 16880641]
[119]
Winterhoff H, Spengler B, Christoffel V, Butterweck V, Löhning A. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity. Maturitas 2003; 44 (Suppl. 1): S51-8.
[http://dx.doi.org/10.1016/S0378-5122(02)00348-1] [PMID: 12609559]
[120]
Zhao Z, Wang W, Guo H, Zhou D. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats. Behav Brain Res 2008; 194(1): 108-13.
[http://dx.doi.org/10.1016/j.bbr.2008.06.030] [PMID: 18655806]
[121]
Mathias NR, Hussain MA. Non-invasive systemic drug delivery: Developability considerations for alternate routes of administration. J Pharm Sci 2010; 99(1): 1-20.
[http://dx.doi.org/10.1002/jps.21793] [PMID: 19499570]
[122]
Ibrahim M, Garcia-Contreras L. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther Deliv 2013; 4(8): 1027-45.
[http://dx.doi.org/10.4155/tde.13.67] [PMID: 23919477]
[123]
Berlinski A. Assessing new technologies in aerosol medicine: Strengths and limitations. Respir Care 2015; 60(6): 833-49.
[http://dx.doi.org/10.4187/respcare.03551] [PMID: 26070578]
[124]
Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain. CNS Drugs 2009; 23(1): 35-58.
[http://dx.doi.org/10.2165/0023210-200923010-00003] [PMID: 19062774]
[125]
Vyas T, Tiwari SB, Amiji MM. Formulation and physiological factors influencing CNS delivery upon intranasal administration. Crit Rev Ther Drug Carr 2006; 23(4)
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v23.i4.20]
[126]
Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: A pilot pharmacokinetic study. Pharmacotherapy 2008; 28(7): 875-82.
[http://dx.doi.org/10.1592/phco.28.7.875] [PMID: 18576902]
[127]
Thompson D, DiMartini A. Nonenteral routes of administration for psychiatric medications. A literature review. Psychosomatics 1999; 40(3): 185-92.
[http://dx.doi.org/10.1016/S0033-3182(99)71234-X] [PMID: 10341530]
[128]
Robbins B, Reiss RA. Amitriptyline absorption in a patient with short bowel syndrome. Am J Gastroenterol 1999; 94(8): 2302-4.
[http://dx.doi.org/10.1111/j.1572-0241.1999.01323.x] [PMID: 10445571]
[129]
Fowler JS, Logan J, Volkow ND, et al. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology 2015; 40(3): 650-7.
[http://dx.doi.org/10.1038/npp.2014.214] [PMID: 25249059]
[130]
Motwani JG, Lipworth BJ. Clinical pharmacokinetics of drug administered buccally and sublingually. Clin Pharmacokinet 1991; 21(2): 83-94.
[http://dx.doi.org/10.2165/00003088-199121020-00001] [PMID: 1884569]
[131]
Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006; 46(2): 164-71.
[http://dx.doi.org/10.1177/0091270005283839] [PMID: 16432268]
[132]
Douzenis A, Michopoulos I, Economopoulos T, Lykouras L, Soldatos CR. Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition. Eur J Cancer Care 2007; 16(3): 289-90.
[http://dx.doi.org/10.1111/j.1365-2354.2006.00735.x] [PMID: 17508951]
[133]
Yap R, Akhileswaran R, Heng CP, Tan A, Hui D. Comfort care kit: Use of nonoral and nonparenteral rescue medications at home for terminally ill patients with swallowing difficulty. J Palliat Med 2014; 17(5): 575-8.
[http://dx.doi.org/10.1089/jpm.2013.0364] [PMID: 24708221]
[134]
Pakyurek M, Pasol E. Sublingually administered fluoxetine for major depression in medically compromised patients. Am J Psychiatry 1999; 156(11): 1833-a.
[135]
Berner B, John VA. Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 1994; 26(2): 121-34.
[http://dx.doi.org/10.2165/00003088-199426020-00005] [PMID: 8162656]
[136]
Scott MA, Letrent KJ, Hager KL, Burch JL. Use of transdermal amitriptyline gel in a patient with chronic pain and depression. Pharmacotherapy 1999; 19(2): 236-9.
[http://dx.doi.org/10.1592/phco.19.3.236.30922] [PMID: 10030776]
[137]
Weiland A, Protus B, Kimbrel J, Grauer P, Hirsh J. Chlorpromazine bioavailability from a topical gel formulation in volunteers. J Support Oncol 2013; 11(3): 144-8.
[http://dx.doi.org/10.12788/j.suponc.0010] [PMID: 24400394]
[138]
van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 1991; 21(1): 11-26.
[http://dx.doi.org/10.2165/00003088-199121010-00002] [PMID: 1717195]
[139]
Mirassou MM. Rectal antidepressant medication in the treatment of depression. J Clin Psychiatry 1998; 59(1): 29.
[http://dx.doi.org/10.4088/JCP.v59n0107a] [PMID: 9491063]
[140]
Storey P, Trumble M. Rectal doxepin and carbamazepine therapy in patients with cancer. N Engl J Med 1992; 327(18): 1318-9.
[http://dx.doi.org/10.1056/NEJM199210293271816] [PMID: 1406828]
[141]
Teter CJ, Phan KL, Cameron OG, Guthrie SK. Relative rectal bioavailability of fluoxetine in normal volunteers. J Clin Psychopharmacol 2005; 25(1): 74-8.
[http://dx.doi.org/10.1097/01.jcp.0000150220.46254.b1] [PMID: 15643102]
[142]
Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry 2018; 75(2): 139-48.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.3739] [PMID: 29282469]
[143]
Gálvez V, Li A, Huggins C, et al. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. J Psychopharmacol 2018; 32(4): 397-407.
[http://dx.doi.org/10.1177/0269881118760660] [PMID: 29542371]
[144]
Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am J Psychiatry 2018; 175(2): 150-8.
[http://dx.doi.org/10.1176/appi.ajp.2017.17040472] [PMID: 28969441]
[145]
Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017; 74(4): 399-405.
[http://dx.doi.org/10.1001/jamapsychiatry.2017.0080] [PMID: 28249076]
[146]
Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord 2018; 227: 219-25.
[http://dx.doi.org/10.1016/j.jad.2017.10.042] [PMID: 29102836]
[147]
Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31-41.
[http://dx.doi.org/10.1001/2013.jamapsychiatry.4] [PMID: 22945416]
[148]
Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71(12): 1381-91.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.1611] [PMID: 25322082]
[149]
Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 2015; 40(6): 1448-55.
[http://dx.doi.org/10.1038/npp.2014.330] [PMID: 25518754]
[150]
Fava M, Memisoglu A, Thase ME, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: A randomized double-blind placebo-controlled trial. Am J Psychiatry 2016; 173(5): 499-508.
[http://dx.doi.org/10.1176/appi.ajp.2015.15070921] [PMID: 26869247]
[151]
Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial. Lancet 2017; 390(10093): 480-9.
[http://dx.doi.org/10.1016/S0140-6736(17)31264-3] [PMID: 28619476]
[152]
Colle R, de Larminat D, Rotenberg S, et al. Pioglitazone could induce remission in major depression: A meta-analysis. Neuropsychiatr Dis Treat 2016; 13: 9-16.
[http://dx.doi.org/10.2147/NDT.S121149] [PMID: 28031713]
[153]
Drevets WC, Zarate CA Jr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. Biol Psychiatry 2013; 73(12): 1156-63.
[http://dx.doi.org/10.1016/j.biopsych.2012.09.031] [PMID: 23200525]
[154]
Furey ML, Pietrini P, Haxby JV, Drevets WC. Selective effects of cholinergic modulation on task performance during selective attention. Neuropsychopharmacology 2008; 33(4): 913-23.
[http://dx.doi.org/10.1038/sj.npp.1301461] [PMID: 17534379]
[155]
Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: Opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging 2018; 3(3): 223-30.
[http://dx.doi.org/10.1016/j.bpsc.2017.11.007] [PMID: 29486863]
[156]
Shatte ABR, Hutchinson DM, Teague SJ. Machine learning in mental health: A scoping review of methods and applications. Psychol Med 2019; 49(9): 1426-48.
[http://dx.doi.org/10.1017/S0033291719000151] [PMID: 30744717]
[157]
Joshi J, Goecke R, Alghowinem S, et al. Multimodal assistive technologies for depression diagnosis and monitoring. J Multimodal User Interfaces 2013; 7(3): 217-28.
[http://dx.doi.org/10.1007/s12193-013-0123-2]
[158]
Zhu Y, Shang Y, Shao Z, Guo G. Automated depression diagnosis based on deep networks to encode facial appearance and dynamics. IEEE Trans Affect Comput 2018; 9(4): 578-84.
[http://dx.doi.org/10.1109/TAFFC.2017.2650899]
[159]
Hallion LS, Ruscio AM. A meta-analysis of the effect of cognitive bias modification on anxiety and depression. Psychol Bull 2011; 137(6): 940-58.
[http://dx.doi.org/10.1037/a0024355] [PMID: 21728399]
[160]
Power M, Dalgleish T. Cognition and emotion: From order to disorder. Psychology press 2015.
[http://dx.doi.org/10.4324/9781315708744]
[161]
McCarthy DM, Pedersen SL, Thompsen DM, Leuty ME. Development of a measure of drinking and driving expectancies for youth. Psychol Assess 2006; 18(2): 155-64.
[http://dx.doi.org/10.1037/1040-3590.18.2.155] [PMID: 16768591]
[162]
Saracino RM, Cham H, Rosenfeld B, Nelson CJ. Confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in oncology with examination of invariance between younger and older patients. Eur J Psychol Assess 2018; 36(2): 229-36.
[http://dx.doi.org/10.1027/1015-5759/a000510] [PMID: 32684745]
[163]
Devlin NJ, Brooks R. EQ-5D and the EuroQol group: Past, present and future. Appl Health Econ Health Policy 2017; 15(2): 127-37.
[http://dx.doi.org/10.1007/s40258-017-0310-5] [PMID: 28194657]
[164]
Trajković G, Starčević V, Latas M, et al. Reliability of the hamilton rating scale for depression: A meta-analysis over a period of 49 years. Psychiatry Res 2011; 189(1): 1-9.
[http://dx.doi.org/10.1016/j.psychres.2010.12.007] [PMID: 21276619]
[165]
Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The montgomery-åsberg depression scale: Reliability and validity. Acta Psychiatr Scand 1986; 73(5): 544-8.
[http://dx.doi.org/10.1111/j.1600-0447.1986.tb02723.x] [PMID: 3751660]
[166]
D’Zurilla TJ, Nezu AM, Maydeu-Olivares A. Social problem-solving inventory-revised. APA PsycNet 2017. Available From: https://psycnet.apa.org/doiLanding?doi=10.1037%2Ft05068-000
[http://dx.doi.org/10.1037/t05068-000]
[167]
Altmann RA, Reynolds CR, Kamphaus RW, Vannest KJ. BASC-3Encyclopedia of Clinical Neuropsychology. Cham: Springer 2018.
[http://dx.doi.org/10.1007/978-3-319-56782-2_1524-2]
[168]
Sun S, Wang S. The children’s depression inventory in worldwide child development research: A reliability generalization study. J Child Fam Stud 2015; 24(8): 2352-63.
[http://dx.doi.org/10.1007/s10826-014-0038-x]
[169]
Neufeld E, O’Rourke N, Donnelly M. Enhanced measurement sensitivity of hopeless ideation among older adults at risk of self-harm: Reliability and validity of Likert-type responses to the Beck Hopelessness Scale. Aging Ment Health 2010; 14(6): 752-6.
[http://dx.doi.org/10.1080/13607860903421052] [PMID: 20686984]
[170]
Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54(5): 573-83.
[http://dx.doi.org/10.1016/S0006-3223(02)01866-8] [PMID: 12946886]

Rights & Permissions Print Cite
Article Metrics
14
4
© 2024 Bentham Science Publishers | Privacy Policy